 KING OF PRUSSIA, Pa., Aug. 3, 2021 PRNewswire -- CSL Behring, a global biotherapeutics leader received U.S. Food and Drug Administration FDA approval for its supplemental request submitted Aug. 30, 2020 for co-packaging of a convenience administration kit along with its product BERINERT, indicated for the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema HAE in adult and pediatric patients. 